Innovative Campaign Focuses on Early Detection and Empowering Education Throughout October CASTRES, France, Sept. 29, 2025 /PRNewswire/ -- Pierre Fabre Laboratories…
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion…
EDMONTON, Alberta, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Breast cancer screening is now being performed in two brand-new mobile units…
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a…
The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer…
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…